SEC Company Response from Entero Therapeutics, Inc. (GRDX) (CIK 0001604191) (GRDX) — Oct 7, 2016
Entero Therapeutics, Inc. (GRDX) (CIK 0001604191)
Date: Oct. 7, 2016 · CIK: 0001604191 · Accession: 0001654954-16-002716
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-212511
Letter
Re: AzurRx BioPharma, Inc.
SEC Connect
October 7, 2016
Securities and Exchange Commission
Fifth Street, N.W.
Washington, D.C.
Registration Statement on Form S-1
File No. 333-212511
Ladies and Gentlemen:
AzurRx BioPharma, Inc. (the “Company”) hereby requests that the effective date of the above-captioned Registration Statement be accelerated to 9:30 a.m. on October 11, 2016, or as soon thereafter as practicable.
The Company acknowledges that (i) should the Securities and Exchange Commission (the “Commission”), or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, such declaration does not foreclose the Commission from taking any action with respect to the Registration Statement; (ii) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and (iii) the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under federal securities laws of the United States.
Very truly
yours,
AZURRX
BIOPHARMA, INC.
Show Raw Text
CORRESP 1 filename1.htm SEC Connect October 7, 2016 Securities and Exchange Commission 450 Fifth Street, N.W. Washington, D.C. 20549 Re: AzurRx BioPharma, Inc. Registration Statement on Form S-1 File No. 333-212511 Ladies and Gentlemen: AzurRx BioPharma, Inc. (the “Company”) hereby requests that the effective date of the above-captioned Registration Statement be accelerated to 9:30 a.m. on October 11, 2016, or as soon thereafter as practicable. The Company acknowledges that (i) should the Securities and Exchange Commission (the “Commission”), or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, such declaration does not foreclose the Commission from taking any action with respect to the Registration Statement; (ii) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and (iii) the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under federal securities laws of the United States. Very truly yours, AZURRX BIOPHARMA, INC. By: /s/ Johan M. (Thijs) Spoor Name: Johan M. (Thijs) Spoor Title: President and Chief Executive Officer